Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...

Analysis of Leqembi's commercial potential and market outlook, with a focus on growth projections and investment ...

The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi ... Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst Eli Lilly's ...

Shares of Eisai Co., Ltd. (OTCMKTS:ESALY – Get Free Report) passed below its 50 day moving average during trading on Friday . The stock has a ... of $17.64 billion, a price-to-earnings ratio ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Short interest in Eisai Co Ltd (OTC:ESALF) increased during the last reporting period, rising from 1.32M to 1.48M. This put -% of the company's publicly available shares short. Short interest for ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

Eisai stock also toppled 3.6% to 10.52 ... He has an outperform rating and 317 price target on Biogen stock, but doesn't list a rating on Eli Lilly stock. Importantly, the FDA advisors seemingly ...

Eisai stock plunged 12.9% to 9.25 ... He kept his outperform rating and 303 price target on Biogen stock. The decision is "somewhat surprising" given physicians have become more comfortable ...

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...